Language
Country/Area
No result found
The mysterious origins of Sandoz: Why this Swiss company became a global pharmaceutical giant
Switzerland's Sandoz Group AG has a significant presence in the global pharmaceutical market, focusing on the production of generic drugs and biosimilars. However, the company's history is full of twists and turns and challenges. From a dye producer in the 19th century to a global pharmaceutical giant today, its development is worth exploring in depth.
History in Review: 1886–1995
The Sandoz story begins in 1886 when founders Alfred Kern and Eduard Sandoz founded "Chemiefirma Kern und Sandoz" in Basel, Switzerland. The initial business focused on the production of dyes such as Blue Scarlet and Mekrin. In 1895, Sandoz turned to pharmaceuticals and launched his first drug, the antipyretic analgesic antipyretic. As demand changed and technology advanced, Sandoz gradually invested in drug research and successfully isolated ergotamine from ergot in 1918 for the prevention and treatment of migraines.
"Beginning in the early 1900s, Sandoz began to innovate and introduce a number of far-reaching drugs, including the synthetic substance LSD."
Over time, Sandoz expanded its business and in 1966 merged with Wander AG, further entering the nutritional products field. In 1994, Sandoz also acquired the famous baby food manufacturer Gerber Products Company, strengthening its influence in the biopharmaceutical field.
Mergers and changes: 1996–2023
In 1996, Sandoz merged with Ciba-Geigy to form Novartis, a world-renowned pharmaceutical giant. During this period, the Sandoz brand name was restricted to over-the-counter drug business only. Over time, the brand was relaunched in 2003 as the global generics division of Novartis.
"Through a series of mergers and acquisitions, Sandoz has established a strong influence in the global market and has become the largest generic drug manufacturer in the German market."
With the independence plan fully underway in 2019, Sandoz has gradually resumed its status as an independent entity, with the initial integration and development steps contributing to its success in generics and biosimilars. In 2023, Novartis officially listed Sandoz independently and made its initial public offering on the Swiss Stock Exchange with a market value of between US$18 billion and US$25 billion, marking Sandoz's return to the international stage.
Challenges and prospects: beyond 2023
In today's market environment, Sandoz not only faces fierce market competition, but also has to deal with price wars after the expiration of drug patents. Despite this, Sandoz continues to attract attention for its innovations in the biosimilars field and plans to expand its product line through acquisitions.
"Sandoz's success is not just about launching new products, but also about its ability to flexibly respond to changing market demands."
For example, Sandoz launched Hyrimoz, a biosimilar to AbbVie's Humira, in 2023, quickly filling a market gap. In the same year, Sandoz also announced that it would acquire a biosimilar drug for vision treatment, demonstrating its determination to actively seek growth in the expanding market.
ConclusionThe history of Sandoz is one of innovation and challenge. From a 19th century dye producer to a global pharmaceutical giant, the company's evolution is not only a corporate success story but also a microcosm of the development of the entire pharmaceutical industry. Looking ahead, it will be an intriguing question whether Sandoz can continue to thrive in the fierce market competition and maintain its commitment to innovative drugs.
